Compare Stocks: AZN, ABBV, JNJ, ASND, and JNJ

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$256.08 -0.8%	$252.66	$190.75 ▼ $267.47	$451.38B	0.3	4.98 million shs	3.22 million shs
ASND Ascendis Pharma A/S	$247.91 -0.6%	$255.74	$186.05 ▼ $282.15	$15.46B	0.39	503,223 shs	314,792 shs
AZN Astrazeneca	$162.83 -1.0%	$171.23	$145.79 ▼ $212.71	$252.33B	0.26	4.35 million shs	2.88 million shs
JNJ Johnson & Johnson	$268.30 +1.0%	$258.88	$173.33 ▼ $276.47	$645.95B	0.24	6.50 million shs	5.76 million shs
JNJ Johnson & Johnson	$268.30 +1.0%	$258.88	$173.33 ▼ $276.47	$645.95B	0.24	6.50 million shs	5.76 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	0.00%	-3.59%	-0.58%	+17.56%	+22.97%
ASND Ascendis Pharma A/S	0.00%	-2.12%	-1.26%	+10.62%	+28.44%
AZN Astrazeneca	0.00%	-1.91%	-5.05%	-12.22%	+1.86%
JNJ Johnson & Johnson	0.00%	-0.88%	+4.87%	+19.16%	+51.85%
JNJ Johnson & Johnson	0.00%	-0.88%	+4.87%	+19.16%	+51.85%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$256.08 -0.8%	$252.66	$190.75 ▼ $267.47	$451.38B	0.3	4.98 million shs	3.22 million shs
ASND Ascendis Pharma A/S	$247.91 -0.6%	$255.74	$186.05 ▼ $282.15	$15.46B	0.39	503,223 shs	314,792 shs
AZN Astrazeneca	$162.83 -1.0%	$171.23	$145.79 ▼ $212.71	$252.33B	0.26	4.35 million shs	2.88 million shs
JNJ Johnson & Johnson	$268.30 +1.0%	$258.88	$173.33 ▼ $276.47	$645.95B	0.24	6.50 million shs	5.76 million shs
JNJ Johnson & Johnson	$268.30 +1.0%	$258.88	$173.33 ▼ $276.47	$645.95B	0.24	6.50 million shs	5.76 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	0.00%	-3.59%	-0.58%	+17.56%	+22.97%
ASND Ascendis Pharma A/S	0.00%	-2.12%	-1.26%	+10.62%	+28.44%
AZN Astrazeneca	0.00%	-1.91%	-5.05%	-12.22%	+1.86%
JNJ Johnson & Johnson	0.00%	-0.88%	+4.87%	+19.16%	+51.85%
JNJ Johnson & Johnson	0.00%	-0.88%	+4.87%	+19.16%	+51.85%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.88	Moderate Buy	$275.95	7.76% Upside
ASND Ascendis Pharma A/S	3.05	Buy	$302.68	22.09% Upside
AZN Astrazeneca	2.75	Moderate Buy	$206.67	26.92% Upside
JNJ Johnson & Johnson	2.80	Moderate Buy	$268.22	-0.03% Downside
JNJ Johnson & Johnson	2.80	Moderate Buy	$268.22	-0.03% Downside

Current Analyst Ratings Breakdown

Latest AZN, ABBV, JNJ, ASND, and JNJ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	ASND Ascendis Pharma A/S	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$345.00
8/27/2026	ASND Ascendis Pharma A/S	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$345.00
8/23/2026	AZN Astrazeneca	CICC Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$198.00
8/20/2026	ABBV AbbVie	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$298.00 ➝ $303.00
8/18/2026	ASND Ascendis Pharma A/S	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$319.00
8/18/2026	ASND Ascendis Pharma A/S	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$319.00
8/17/2026	ABBV AbbVie	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$295.00 ➝ $300.00
8/14/2026	ASND Ascendis Pharma A/S	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$280.00 ➝ $290.00
8/14/2026	ASND Ascendis Pharma A/S	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$325.00 ➝ $341.00
8/14/2026	ASND Ascendis Pharma A/S	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$345.00 ➝ $329.00
8/13/2026	ASND Ascendis Pharma A/S	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$333.00

(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$61.16B	7.40	$15.18 per share	16.87	($3.33) per share	-76.90
ASND Ascendis Pharma A/S	$814.57M	18.99	N/A	N/A	$26.78 per share	9.26
AZN Astrazeneca	$61.37B	4.12	$12.93 per share	12.59	$32.48 per share	5.01
JNJ Johnson & Johnson	$94.19B	6.86	$14.14 per share	18.98	$35.26 per share	7.61
JNJ Johnson & Johnson	$94.19B	6.86	$14.14 per share	18.98	$35.26 per share	7.61

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.23B	$3.54	72.34	15.86	0.85	9.80%	-422.07%	14.34%	10/30/2026 (Estimated)
ASND Ascendis Pharma A/S	-$258M	$12.89	19.23	24.30	N/A	70.99%	32.54%	7.71%	11/11/2026 (Estimated)
AZN Astrazeneca	$10.23B	$6.69	24.34	14.31	1.41	17.02%	31.45%	13.20%	10/30/2026 (Estimated)
JNJ Johnson & Johnson	$26.80B	$8.63	31.09	20.96	2.56	21.48%	32.42%	13.35%	10/13/2026 (Estimated)
JNJ Johnson & Johnson	$26.80B	$8.63	31.09	20.96	2.56	21.48%	32.42%	13.35%	10/13/2026 (Estimated)

Latest AZN, ABBV, JNJ, ASND, and JNJ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	ASND Ascendis Pharma A/S	$1.71	$1.0270	-$0.6830	$3.23	$376.75 million	$387.22 million
7/31/2026	Q2 2026	ABBV AbbVie	$3.61	$3.65	+$0.04	$2.03	$16.80 billion	$16.99 billion
7/27/2026	Q2 2026	AZN Astrazeneca	$2.50	$2.63	+$0.13	$0.8050	$15.44 billion	$15.38 billion
7/15/2026	Q2 2026	JNJ Johnson & Johnson	$2.84	$2.90	+$0.06	$2.27	$25.06 billion	$25.31 billion
7/15/2026	Q2 2026	JNJ Johnson & Johnson	$2.84	$2.90	+$0.06	$2.27	$25.06 billion	$25.31 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.92	2.70%	+6.80%	195.48%	53 Years
ASND Ascendis Pharma A/S	N/A	N/A	N/A	N/A	N/A
AZN Astrazeneca	$4.34	2.67%	+2.30%	64.87%	N/A
JNJ Johnson & Johnson	$5.36	2.00%	+5.25%	62.11%	64 Years
JNJ Johnson & Johnson	$5.36	2.00%	+5.25%	62.11%	64 Years

Latest AZN, ABBV, JNJ, ASND, and JNJ Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/15/2026	JNJ Johnson & Johnson	quarterly	$1.34	1.96%	8/25/2026	8/25/2026	9/8/2026
7/15/2026	JNJ Johnson & Johnson	quarterly	$1.34	1.96%	8/25/2026	8/25/2026	9/8/2026
6/18/2026	ABBV AbbVie	quarterly	$1.73	2.83%	7/15/2026	7/15/2026	8/14/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	N/A	0.81	0.69
ASND Ascendis Pharma A/S	0.27	2.99	2.32
AZN Astrazeneca	0.47	0.89	0.67
JNJ Johnson & Johnson	0.44	1.09	0.81
JNJ Johnson & Johnson	0.44	1.09	0.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
ASND Ascendis Pharma A/S	N/A
AZN Astrazeneca	20.35%
JNJ Johnson & Johnson	69.55%
JNJ Johnson & Johnson	69.55%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.06%
ASND Ascendis Pharma A/S	40.00%
AZN Astrazeneca	N/A
JNJ Johnson & Johnson	0.16%
JNJ Johnson & Johnson	0.16%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	57,000	1.77 billion	1.77 billion	Optionable
ASND Ascendis Pharma A/S	1,189	62.38 million	37.43 million	Optionable
AZN Astrazeneca	96,100	1.55 billion	N/A	N/A
JNJ Johnson & Johnson	138,200	2.41 billion	2.41 billion	Optionable
JNJ Johnson & Johnson	138,200	2.41 billion	2.41 billion	Optionable

AZN, ABBV, JNJ, ASND, and JNJ Headlines

Recent News About These Companies

How a 79-Year-Old Widow Built a $6,100 Monthly Paycheck Around O, JNJ, and PFF

August 30 at 3:07 PM | 247wallst.com

How a 79-Year-Old Widow Built a $6,100 Monthly Paycheck Around O, JNJ, and PFF

August 30 at 10:06 AM | aol.comA

Johnson & Johnson $JNJ Shares Sold by Hikari Power Ltd

August 30 at 4:40 AM | marketbeat.com

Johnson & Johnson $JNJ Stock Position Cut by Persistent Asset Partners Ltd

August 30 at 4:40 AM | marketbeat.com

Mitsubishi UFJ Asset Management Co. Ltd. Buys 420,556 Shares of Johnson & Johnson $JNJ

August 30 at 4:40 AM | marketbeat.com

Trust Co. of Vermont Acquires New Shares in Johnson & Johnson $JNJ

August 30 at 4:40 AM | marketbeat.com

MidFirst Bank Decreases Stock Holdings in Johnson & Johnson $JNJ

August 30 at 4:39 AM | marketbeat.com

Oak Barrel Wealth Advisory LLC Buys Shares of 3,933 Johnson & Johnson $JNJ

August 30 at 4:39 AM | marketbeat.com

Deutsche Bank AG Has $3.98 Billion Stake in Johnson & Johnson $JNJ

August 30 at 3:35 AM | marketbeat.com

Commerzbank Aktiengesellschaft FI Raises Stock Position in Johnson & Johnson $JNJ

August 30 at 3:35 AM | marketbeat.com

BlackRock Inc. Has $53.87 Billion Position in Johnson & Johnson $JNJ

August 30 at 3:21 AM | marketbeat.com

Beverly Hills Private Wealth LLC Sells 8,797 Shares of Johnson & Johnson $JNJ

August 30 at 3:21 AM | marketbeat.com

Forget Nvidia. Johnson & Johnson and 2 Other AI Stocks Are Beating the Market by 29 Points.

August 30 at 2:51 AM | finance.yahoo.com

Johnson & Johnson Stock: Is JNJ Outperforming the Consumer Staples Sector?

August 29 at 1:31 PM | barchart.com

Simplicity Wealth LLC Boosts Stock Holdings in Johnson & Johnson $JNJ

August 29 at 5:12 AM | marketbeat.com

Global Retirement Partners LLC Makes New $17.05 Million Investment in Johnson & Johnson $JNJ

August 29 at 5:12 AM | marketbeat.com

Compass Capital Management Inc. Has $60.12 Million Position in Johnson & Johnson $JNJ

August 29 at 4:04 AM | marketbeat.com

Continuum Advisory LLC Sells 4,074 Shares of Johnson & Johnson $JNJ

August 29 at 4:03 AM | marketbeat.com

Flputnam Investment Management Co. Purchases 27,425 Shares of Johnson & Johnson $JNJ

August 29 at 4:03 AM | marketbeat.com

Argent Trust Co Increases Position in Johnson & Johnson $JNJ

August 29 at 3:12 AM | marketbeat.com

AMG National Trust Bank Reduces Stake in Johnson & Johnson $JNJ

August 29 at 3:08 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AZN, ABBV, JNJ, ASND, and JNJ Company Descriptions

AbbVie NYSE:ABBV

$256.08 -2.07 (-0.80%)

As of 08/28/2026 03:58 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Ascendis Pharma A/S NASDAQ:ASND

$247.91 -1.45 (-0.58%)

As of 08/28/2026 04:00 PM Eastern

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Astrazeneca NYSE:AZN

$162.83 -1.69 (-1.03%)

As of 08/28/2026 03:58 PM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Johnson & Johnson NYSE:JNJ

$268.30 +2.53 (+0.95%)

As of 08/28/2026 03:58 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson NYSE:JNJ

$268.30 +2.53 (+0.95%)

As of 08/28/2026 03:58 PM Eastern

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AZN, ABBV, JNJ, ASND, and JNJ Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AZN, ABBV, JNJ, ASND, and JNJ Earnings

Compare Dividends

Latest AZN, ABBV, JNJ, ASND, and JNJ Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AZN, ABBV, JNJ, ASND, and JNJ Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AZN, ABBV, JNJ, ASND, and JNJ Company Descriptions

AbbVie NYSE:ABBV

Ascendis Pharma A/S NASDAQ:ASND

Astrazeneca NYSE:AZN

Johnson & Johnson NYSE:JNJ

Johnson & Johnson NYSE:JNJ

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools